The mass production of systematic reviews about COVID-19: An analysis of PROSPERO records

Lara Dotto 1 | Mateus de Azevedo Kinalski 2 | Pablo Soares Machado 3 | Gabriel Kalil Rocha Pereira 3 | Rafael Sarkis-Onofre 1 | Mateus Bertolini Fernandes dos Santos 2

1 Graduate Program in Dentistry, Meridional College/IMED, Passo Fundo, Brazil
2 Graduate Program in Dentistry, Federal University of Pelotas (UFPEL), Pelotas, RS, Brazil
3 Post-Graduate Program in Oral Sciences, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil

Correspondence
Rafael Sarkis-Onofre, Graduate Program in Dentistry, Meridional Faculty/IMED, Passo Fundo, Brazil.
Email: rafaelonofre@gmail.com

Abstract
Objective: This study aimed to assess the characteristics of different designs of systematic reviews (SRs) registered in the International Prospective Register of Systematic Reviews (PROSPERO) about COVID-19.

Methods: The search was performed in the PROSPERO database using the strategy proposed by the database and considered only human studies. The last date of the search was April 27, 2020. Full text of all records was accessed, and data were extracted by a single researcher, which was further double-checked by another researcher. A descriptive analysis was performed considering record characteristics using tables.

Results: We included 564 records from which the vast majority were registered as SRs (n = 513, 91%). In general, we found poor reporting and missing or confusing information, since 84% of the records (n = 474) did not report the full search that would be adopted, 16% (n = 90) did not report clearly the databases that would be used, and 49.1% (n = 277) did not report the number of primary outcomes. The main focus of most of the records involved clinical, epidemiological, complication, and laboratory characteristics (n = 173, 30.7%) or the treatment of COVID-19 (n = 138, 24.5%).

Conclusion: A large number of SRs about COVID-19 have been conducted, and many of the assessed records were poorly reported and would be difficult to replicate. Besides, collected data points to an epidemic of redundant reviews on COVID-19.

KEYWORDS
quality, register, reporting, systematic reviews

1 INTRODUCTION

The novel coronavirus pandemic is heavily impacting almost all countries in the world, both from health and economic perspectives. At the moment, about 350,000 (updated data can be accessed in: https://www.worldometers.info/coronavirus/) people have died due to coronavirus disease 2019 (COVID-19) complications. To reduce these numbers, researchers are responding at breathtaking speed, conducting everything from basic research to controlled trials to test possible treatment options1; however, at present, no treatment, prophylaxis, or
vaccine is effective in treating COVID-19, though countries that were highly affected by the pandemic tried to redirect different drugs to the treatment of COVID-19.

Although there is an urgency in finding an effective answer to manage COVID-19, no definitive response will be found without proper research design, conduct, and report, and there are already some retractions in the literature about studies for the treatment of COVID-19. Another example of the importance of well-designed and conducted studies during the pandemic is an earlier study conducted on a small sample of patients that reported a positive effect of the adjunctionive use of hydroxychloroquine and azithromycin in critical patients, reducing the convalescence time and fatality rates. However, it turned out that a larger multinational real-world analysis not only did not confirm these previous findings but also observed an increased hazard for a clinically significant occurrence of ventricular arrhythmias and in-hospital death with COVID-19. The adjunctive use of other drugs was also considered and debated (as dexamethasone, favipiravir, ivermectin, remdesivir), but none prove to be efficient, to date.

It is well known that systematic reviews with meta-analysis can provide the best levels of evidence being an important tool to define health care strategies and resource allocation planning. Previous papers have warned about the risk of low quality and duplication of ongoing research that could result in "massive waste in research." Still, in this sense, the Cochrane Handbook for Systematic Reviews of Interventions emphasizes that a systematic review protocol should be developed and registered in specific databases before its start, to avoid reporting bias or the change of the previously planned study design. However, a study by Tricco et al observed that a third of systematic reviews changed or did not specify their primary outcome on the register and that only 18% of published systematic reviews have previously been registered.

Considering these aspects, this study aimed to assess the characteristics of different designs of systematic reviews (SR) records registered in the International Prospective Register of Systematic Reviews (PROSPERO) about COVID-19.

2 METHODS

The study protocol was registered in the open science framework (OSF) and is available at the following link: https://osf.io/9umqj/.

2.1 Inclusion criteria and search

We selected SRs or any other knowledge synthesis designs (ie, rapid reviews, umbrella reviews, and living reviews) about COVID-19 registered in the PROSPERO database. Studies were included regardless of review questions and characteristics. The search was performed in the PROSPERO database using the strategy proposed by the database to identify study records about COVID-19, considering only human studies (Supporting Information). The last search was conducted on April 27, 2020.

2.2 Records screening

Records identified in PROSPERO were downloaded in Endnote format as control of included studies, and the records’ full texts were accessed directly on the PROSPERO platform. Only the first version of each record was considered at this time to standardize the records because it is possible to change information during the study development.

We created a standardized form using the Excel software, which was tested by all the researchers to reach a consensus of data collections.

2.3 Data extraction

Records were divided among three researchers to perform data extraction, and after, one researcher double-checked all data. In order to register an SR, the PROSPERO database requires different information varying from the review title, details about the organization, and authors responsible by the study to details related to the methodology. We decide to collect data related to the characteristics of the study and methodological data related to study replication. The following data was collected: registration date, country of conduct, funding (based on the Cochrane Effective Practice and Organisation of Care Review Group recommendations), review question/s, databases, description of full search strategy, type of study to be included, intervention studied, number of primary outcomes in the record (classified as “Unclear” when it was impossible to judge the number of primary outcomes), number of secondary outcomes in the record (classified as “Unclear” when it was impossible to judge the number of secondary outcomes), synthesis strategy, additional analysis, risk of bias tool, type, and method of review. Also, we categorized the different tested treatments in records of COVID-19 treatments.

2.4 Data analysis

A descriptive analysis was performed considering the characteristics of the records using proportions, median, and IQR through tables. To map different tested treatments, we also created a table displaying all records about COVID-19 treatments and a map depicting the origin and distribution of SR records using the Adobe Photoshop CS6 software.

3 RESULTS

The search yielded 574 records, and 10 were excluded because the full texts were not identified in the PROSPERO platform during the data extraction phase. The majority of these studies were registered as SRs (n = 513, 91%; Table 1). The conduct of the majority of the registered records (n = 210, 37.2%; Table 1) was not started before April 27, 2020, and only four studies had already performed data extraction/analysis (data extraction n = 1, 0.2%; data analysis n = 3, 0.5%; Table 1). The great majority of the records did not report the existence...
## TABLE 1  Characteristics of systematic review registration records/PROSPERO records included (n = 564)

| Characteristics                        | n  | %    |
|----------------------------------------|----|------|
| **Type of systematic review**          |    |      |
| Systematic review                      | 513| 91.0%|
| Rapid review                           | 26 | 4.6% |
| Living systematic review               | 17 | 3.0% |
| Network meta-analysis                   | 3  | 0.5% |
| Rapid and living systematic review      | 2  | 0.3% |
| Qualitative systematic review          | 1  | 0.2% |
| Umbrella review                        | 1  | 0.2% |
| Unclear                                | 1  | 0.2% |
| **Last stage started**                 |    |      |
| Not started                            | 210| 37.2%|
| Preliminary searches                    | 130| 23.0%|
| Formal screening of search results     | 123| 21.1%|
| Risk of bias (quality) assessment      | 7  | 1.2% |
| Data extraction                        | 1  | 0.2% |
| Data analysis                          | 3  | 0.5% |
| **Conflict of interest**               |    |      |
| Not reported                           | 501| 88.3%|
| None                                   | 55 | 9.7% |
| Yes                                    | 8  | 1.4% |
| **Funding**                            |    |      |
| No funding                             | 370| 65.6%|
| Governmental organization              | 107| 19.0%|
| Unclear                                | 31 | 5.5% |
| Mixed                                  | 20 | 3.5% |
| Other                                  | 15 | 2.7% |
| Research funding body                  | 9  | 1.6% |
| Charitable trust                       | 5  | 0.9% |
| Health care provider organization      | 5  | 0.9% |
| Commercial organization                | 2  | 0.3% |
| **Main focus**                         |    |      |
| Clinical, epidemiological, complication, and laboratory characteristics | 173| 30.7%|
| Treatment                              | 138| 24.5%|
| Unclear                                | 68 | 12.1%|
| 2 or more                              | 51 | 9.0% |
| Other                                  | 41 | 7.3% |
| Psychological questions                | 40 | 7.1% |
| Diagnosis                              | 22 | 3.9% |
| Association of factors                 | 17 | 3.0% |
| Prevention                             | 14 | 2.5% |
| **Full search not reported**           | 474| 84.0%|
| **Number of databases considered**     |    |      |
| “Unclear”                              | 90 | 16.0%|

(Continues)
### TABLE 1  (Continued)

| Characteristics                                      | n   | %   |
|-------------------------------------------------------|-----|-----|
| Number of databases (median/IQR)                      | 4   | 3-6 |
| Databases searched                                    |     |     |
| MEDLINE/PubMed                                        | 557 | 98.9%|
| SCOPUS                                                | 135 | 24.0%|
| EMBASE                                                | 434 | 77.1%|
| Web of Science or Web of Knowledge                    | 239 | 42.4%|
| GoogleScholar                                         | 113 | 20.1%|
| Others                                                | 457 | 81.2%|
| Number of primary outcomes considered “Unclear”       | 277 | 49.1%|
| Number of primary outcome (median/IQR)                | 2   | 1-3 |
| Number of secondary outcomes considered “Unclear”     | 176 | 31.2%|
| Number of secondary outcomes (median/IQR)             | 0   | 0-2 |
| Synthesis strategy                                    |     |     |
| Meta-analysis                                          | 333 | 59.0%|
| Descriptive/narrative and meta-analysis                | 126 | 22.3%|
| Descriptive analysis                                  | 48  | 8.5% |
| Narrative analysis                                    | 25  | 4.4% |
| Unclear                                               | 15  | 2.7% |
| Network meta-analysis                                 | 11  | 1.9% |
| Other                                                 | 6   | 1.1% |
| Additional analysis                                   |     |     |
| Subgroup                                              | 386 | 68.4%|
| None                                                  | 101 | 17.9%|
| Subgroup analysis and one or more additional analysis | 56  | 9.9% |
| Unclear                                               | 17  | 3.0% |
| Publication                                           | 3   | 0.5% |
| Sensitivity analysis                                  | 1   | 0.2% |
| Risk of bias tool reported                            |     |     |
| Cochrane risk of bias tools                           | 147 | 26.1%|
| Two or more different tools                           | 128 | 22.7%|
| Newcastle Ottawa                                      | 81  | 14.4%|
| Other                                                 | 79  | 14.0%|
| Unclear                                               | 63  | 11.2%|
| Joanna Briggs Institute Critical Appraisal Checklist   | 16  | 2.8% |
| NHI tools                                             | 16  | 2.8% |
| None                                                  | 16  | 2.8% |
| GRADE                                                 | 15  | 2.7% |
| Not reported                                           | 3   | 0.5% |

(Continues)
or the absence of conflict of interest \((n = 501, 88.3\%; \text{Table 1})\), and 34.4% of the records received some type of funding (Table 1).

The main focus of most of the records involved clinical, epidemiological, complication, and laboratory characteristics \((n = 173, 30.7\%; \text{Table 1})\) or the treatment of COVID-19 \((n = 138, 24.5\%; \text{Table 1})\). Despite that, 84% of the records \((n = 474, \text{Table 1})\) did not report the full search that would be adopted. Also, in 16% of the assessed records, even the databases that would be used were unclear \((n = 90, \text{Table 1})\). The number of primary outcomes was unclear in 49.1% of the records \((n = 277, \text{Table 1})\). The most proposed synthesis strategy method was meta-analysis \((n = 333, 59\%; \text{Table 1})\), and, as additional analysis, subgroup analysis \((n = 386, 68.4\%; \text{Table 1})\). The risk of bias tool claimed to be used varied between Cochrane risk of bias tools \((n = 147, 26.1\%; \text{Table 1})\), Newcastle-Ottawa tool \((n = 81, 14.4\%; \text{Table 1})\), or the use of two or more different tools \((n = 128, 22.7\%; \text{Table 1})\).

Table 2 describes the options of treatments that are proposed to be explored, and notably, there was a large variety of treatment options. Despite that, it should be emphasized that there were 36 records exploring the effects of Chinese medicine, and 16 focused on chloroquine/hydroxychloroquine records, which could be indicative of a risk for duplication of data and overlapping of such studies.

Table 3 shows the ten countries that contributed the most records. China had the most contribution with 201 records (35.6%), followed by the United Kingdom \((n = 67, 11.9\%)\) and Brazil \((n = 44, 7.8\%)\).

4 | DISCUSSION

We assessed the characteristics of the SR records on COVID-19 in PROSPERO, the amount of which is exponentially increasing (as of May 26, 2020, the number of human records registered reached 1017). Without a doubt, there are signs of poor reporting of the records (absence of proper description of outcomes considered, databases explored, a full search strategy that would be adopted, among other important method characteristics), resulting in imprecise studies/results, which would be difficult to replicate. Also, our results demonstrated a great duplication of records assessing similar/equal topics, unleashing a “massive waste in research,” as previously suggested by Glasziou et al.\(^1\) Page et al\(^13\) state that duplicates systematic reviews waste time and resources, creating extra work for health care providers and other users who need to determine what unique information, if any, each review provides. Duplication can also create confusion when SRs addressing the same research question reach conflicting findings.\(^14\) It is important to bear in mind that some duplicated reviews can be explained by the fact that there is a gap between the submission of a record and its publication. This gap could take around 30 days, as it is currently stated on the PROSPERO website. Also, due to high traffic and increased number of registers, some of the records can be published without being checked by the PROSPERO staff if the gap from submission to publishing exceeds 30 days.

In our analysis, China was the country that had registered the most significant number of records. It is clear that many researchers from different regions around the world desire to contribute toward addressing the COVID-19 pandemic and that such attempt could lead to duplication of SRs being conducted. However, that focus would be better expended on creating strategies of collaboration among different research groups to provide more reliable data.\(^13\)

It is also understandable that during a pandemic period, the time-consuming peer-review process of records submitted for registering platforms may become compromised, but this only emphasizes the need for researchers to carefully consider and evaluate if there is not already a previous record on any given theme. If a register already exists, perhaps looking for a collaboration to develop a better record would be wiser than creating a duplicate study. Another factor to consider is that the urgency of well-designed studies and high-quality data to provide high scientific evidence is not rapidly provided\(^12,15,16\); thus, it is understandable and necessary that SRs are replicated through time.\(^13\)

A replicated SR is defined as using the same or very similar methods as a previous SR to determine whether comparable results are obtained or intentionally broadening or narrowing the question addressed in a previous review to check how operationalization of con-

| Characteristics | \(n\) | % |
|-----------------|------|---|
| **Study designs included** | | |
| One or more observational studies | 131 | 23.2% |
| Randomized and/or nonrandomized controlled trials and observational studies | 122 | 21.6% |
| All study designs | 100 | 17.7% |
| Randomized controlled trials | 99 | 17.5% |
| Others | 39 | 6.9% |
| Unclear | 35 | 6.2% |
| Randomized and nonrandomized controlled trials | 23 | 4.1% |
| Clinical studies | 9 | 1.6% |
| Studies performed on human beings | 6 | 1.1% |

| Characteristic | \(n\) |
|----------------|------|
| Study designs included | |
| One or more observational studies | 131 |
| Randomized and/or nonrandomized controlled trials and observational studies | 122 |
| All study designs | 100 |
| Randomized controlled trials | 99 |
| Others | 39 |
| Unclear | 35 |
| Randomized and nonrandomized controlled trials | 23 |
| Clinical studies | 9 |
| Studies performed on human beings | 6 |

**Table 1** (Continued)
| Treatments                                                                 | n  | %   |
|---------------------------------------------------------------------------|----|-----|
| Unclear                                                                   | 19 | 11.9|
| Traditional Chinese medicine                                              | 19 | 11.9|
| Chloroquine and/or hydroxychloroquine                                     | 12 | 7.5 |
| Traditional Chinese and Western medicine                                  | 6  | 3.8 |
| Lianhua Qingwen capsules                                                  | 5  | 3.1 |
| Blood components                                                          | 5  | 3.1 |
| Acupuncture                                                               | 4  | 2.5 |
| Corticosteroids                                                           | 4  | 2.5 |
| Different types of treatment                                              | 4  | 2.5 |
| Favipiravir                                                               | 3  | 1.9 |
| Lopinavir/ritonavir                                                       | 3  | 1.9 |
| Pharmacological treatment                                                  | 3  | 1.9 |
| Physiotherapy techniques                                                  | 2  | 1.3 |
| Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers | 2  | 1.3 |
| Atazanavir                                                                | 2  | 1.3 |
| Chloroquine plus azithromycin                                            | 2  | 1.3 |
| Extracorporeal membrane oxygenation                                      | 2  | 1.3 |
| External treatment of traditional Chinese medicine                        | 2  | 1.3 |
| Immunosuppressive drugs                                                   | 2  | 1.3 |
| Interferon                                                                | 2  | 1.3 |
| Jinhua Qinggan granule                                                    | 2  | 1.3 |
| Noninvasive ventilation                                                   | 2  | 1.3 |
| Qing Fei Bai Du decoction                                                | 2  | 1.3 |
| Remdesivir                                                                | 2  | 1.3 |
| Ribavirin                                                                 | 2  | 1.3 |
| Chinese Herbal medicine                                                   | 2  | 1.3 |
| Traditional medicine as adjunctive therapy                               | 2  | 1.3 |
| Xuebijing injection                                                       | 2  | 1.3 |

(Continues)
| Treatments                                                                 | n  | %  |
|---------------------------------------------------------------------------|----|----|
| Favipiravir and remdesivir                                                | 1  | 0.6|
| Interleukin 1 inhibitor agents (specifically Anakinra) VS anti-IL6 monoclonal antibodies (tocilizumab, sarilumab, siltuximab) | 1  | 0.6|
| Traditional Chinese medicine injections                                  | 1  | 0.6|
| Volume-controlled ventilation                                             | 1  | 0.6|
| Adjuvant pharmacologic therapy, standard care, definitive pharmacologic therapy, combined definitive pharmacologic | 1  | 0.6|
| Advanced respiratory support; basic respiratory support                   | 1  | 0.6|
| All suggested pharmacological therapies                                   | 1  | 0.6|
| Arbidol                                                                   | 1  | 0.6|
| Antiparasitic drugs                                                       | 1  | 0.6|
| Antiviral drugs                                                           | 1  | 0.6|
| Bacillus Calmette–Guérin vaccine (BCG) vaccination                       | 1  | 0.6|
| Chinese exercise                                                          | 1  | 0.6|
| Combination of traditional Chinese and Western medicine                   | 1  | 0.6|
| Convalescent plasma transfusion vs standard care                         | 1  | 0.6|
| Convalescent plasma or hyperimmune immunoglobulin                        | 1  | 0.6|
| Enoxaparin or fondaparinux                                                | 1  | 0.6|
| Favipiravir, remdesivir, galidesivir, ivermectin, oseltamivir, ganciclovir, lopinavir/ ritonavir, darunavir, chloroquine, hydroxychloroquine, arbidol, azithromycin, amoxicillin, moxifloxacin, ceftriaxone, antifungals, androgen receptor blockers, tea, and traditional Chinese medicine | 1  | 0.6|
| Hydroxychloroquine vs azithromycin                                        | 1  | 0.6|
| Hydroxychloroquine vs standard treatment                                  | 1  | 0.6|
| Interferons alone or in combination with other drugs                      | 1  | 0.6|
| Lopinavir combined with ritonavir                                          | 1  | 0.6|
| Integrative traditional Chinese and Western medicine                      | 1  | 0.6|
| Interferon, lopinavir, ritonavir, ribavirin, remdesivir                   | 1  | 0.6|
| Rheumatic disease therapy                                                 | 1  | 0.6|
| Monoclonal antibodies                                                     | 1  | 0.6|
| Macrolides                                                                | 1  | 0.6|

(Continues)
| Treatments                                                   | n | %   |
|--------------------------------------------------------------|---|-----|
| Mesenchymal stem cell-based therapy                           | 1 | 0.6 |
| Vitamin C                                                    | 1 | 0.6 |
| Tocilizumab alone. tocilizumab combination therapy with antivirals and/or other drugs | 1 | 0.6 |
| Siddha medicine                                              | 1 | 0.6 |
| Pharmacological interventions, fluid therapy, invasive or noninvasive ventilation, or similar interventions | 1 | 0.6 |
| Traditional Chinese exercise                                 | 1 | 0.6 |
| Moxibustion                                                  | 1 | 0.6 |
| Tai Chi                                                      | 1 | 0.6 |
| Traditional Chinese medicine nonpharmacological interventions | 1 | 0.6 |
| Pharmacologic and nonpharmacologic                            | 1 | 0.6 |
| Massage therapy                                              | 1 | 0.6 |

**TABLE 3** Illustration of the 10 countries that contributed the most records

| Position | Country       | n  | %  |
|----------|---------------|----|----|
| 1        | China         | 201| 35.6|
| 2        | England       | 67 | 11.9|
| 3        | Brazil        | 44 | 7.8 |
| 4        | Canada        | 26 | 4.6 |
| 5        | India         | 20 | 3.6 |
| 6        | USA           | 18 | 3.2 |
| 7        | Iran          | 16 | 2.8 |
| 8        | Italy         | 14 | 2.5 |
| 9        | Ethiopia      | 11 | 2.0 |
| 10       | Australia     | 8  | 1.4 |
|          | Spain         | 8  | 1.4 |

cept in the previous review influenced the results. Thus, replication of reviews could be important for evidence syntheses, especially during special times such as the COVID-19 pandemic. It is important to emphasize, though, that the uncontrolled duplication of SRs at the same time is not categorized as replication, and the present study identified what seems to be more likely an epidemic of redundant reviews on COVID-19. Based on our results, there is evidence that most of the SR records in PROSPERO about COVID-19 are impossible to be replicated because some information, such as full search strategy and details about outcomes, were poorly reported.

A few limitations of our analyses should be mentioned. First, although GRADE is not a risk of bias tool, many authors cited the use of such tool in their PROSPERO records and, therefore, we have opted to include it in the table about the risk of bias tool used; however, it must be emphasized that those records that reported the use of GRADE misused such tool. The results should be interpreted with caution since we performed a cross-sectional analysis, and during the year 2020, more and more records are being created on PROSPERO about COVID-19; hence, the mass production of systematic reviews reported in our study could be even bigger. Our assessment was based on the report of the PROSPERO records, and it is possible that certain studies were performed more rigorously than specified in the record. Finally, we assessed only the first version of each PROSPERO record, and it is possible that such records were or will be modified. The assessment of only the first version of the record aimed to standardize the records and to evaluate the first body of the planned methods of these reviews. In the future, it will be possible to monitor changes that were made during the execution of the systematic review. In this sense, although changes in PROSPERO records are acceptable when justified, they may reflect mistakes on planning or lack of expertise on the analysis. It has been greatly defended that the protocol elaboration is a crucial step in the systematic review process. Thus it should be carefully and adequately planned, registered, and made freely accessible to the scientific community as a reflection of good research practice. Also, it is important to highlight that guidelines such as PRISMA-P are available.
and are strongly recommended to enable quality reports of systematic review protocols creation.²⁰

In conclusion, a massive number of SRs about COVID-19 have been conducted, whose PROSPERO records present varied characteristics. Furthermore, many of the assessed records were poorly reported and would be difficult, if not impossible, to replicate, but these results should be interpreted with caution. Even considering that pandemic periods demand urgency in evidence compilation, it is mandatory to conduct research with good practices, focusing on quality reporting, adopting the necessary methods to access the knowledge on the theme, and attempting to establish collaborations among research groups rather than duplicate SR studies.

ACKNOWLEDGMENTS
RSO is funded in part by Meridional Foundation (Passo Fundo—Brazil). LD, PSM, and MAK are funded by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001. This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ORCID
Rafael Sarkis-Onofre https://orcid.org/0000-0002-1514-7879

REFERENCES
1. Glasziou PP, Sanders S, Hoffmann T. Waste in COVID-19 research. BMJ (Clin Res Ed.). 2020;369:m1847.
2. Alexander PE, Debono VB, Mammen MJ, et al. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. J Clin Epidemiol. 2020;123:120-126.
3. Mehra M, Desai S, Rutschitzka F, Patel A. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020.
4. Mehra MR, Rutschitzka F, Patel AN. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395:1820.
5. Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;34:101663.
6. Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020;35:100684.
7. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir—a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6:45-51.
8. Sisay M. Available evidence and ongoing clinical trials of remdesivir: could it be a promising therapeutic option for COVID-19? Front Pharmacol. 2020;11:791.
9. Theoharides TC, Conti P. Dexamethasone for COVID-19? Not so fast. J Biol Regul Homeost Agents. 2020;34(3):1241-1243.
10. Friedman L, Furfurbe D, DeMets D. Fundamentals of Clinical Trials. New York: Springer; 2010.
11. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. 2019. Available from www.hanbook.cochrane.org.2019.
12. Tricco AC, Cogo E, Page MJ, et al. A third of systematic reviews changed or did not specify the primary outcome: a PROSPERO register study. J Clin Epidemiol. 2016;79:46-54.
13. Page M, Welch V, Haddaway N, Karunananthan S, Maxwell L, Tugwell P. One more time’: why replicating some syntheses of evidence relevant to COVID-19 makes sense. J Clin Epidemiol. 2020;125:179-182.
14. Hacke C, Nunan D. Discrepancies in meta-analyses answering the same clinical question were hard to explain: a meta-epidemiological study. J Clin Epidemiol. 2020;119:47-56.
15. Shokraneh F, Russell-Rose T. Lessons from COVID-19 to future evidence synthesis efforts: first living search strategy and out of date scientific publishing and indexing industry (submitted). J Clin Epidemiol. 2020;123:171-173.
16. Knottnerus JA, Tugwell P. Methodological challenges in studying the COVID-19 pandemic crisis. J Clin Epidemiol. 2020;121:A5-A7.
17. Karunananthan S, Maxwell LJ, Welch V, et al. When and how to replicate systematic reviews. Cochr Datab Syst Rev (Online). 2020(2):1-9.
18. Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;1:2.
19. Moher D, Booth A, Stewart L. How to reduce unnecessary duplication: use PROSPERO. BJOG. 2014;121:784-786.
20. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Dotto L, Kinalske MdA, Machado PS, Pereira GKR, Sarkis-Onofre R, dos Santos MBF. The mass production of systematic reviews about COVID-19: An analysis of PROSPERO records. J Evid Based Med. 2021;14:56–64. https://doi.org/10.1111/jebm.12426